Literature DB >> 173653

Passive immunization in experimental Herpesvirus hominis infection of newborn mice.

F Luyet, D Samra, A Soneji, M I Marks.   

Abstract

Infection of newborn mice with Herpesvirus hominis type 2(HVH-2) was used as an experimental model of disseminated HVH infection in newborn humans. Mice were challenged with 103 plaque-forming units of HVH-2 intranasally and were given 0.2 ml of rabbit serum intraperitoneally. Passive immunizations with rabbit anti-HVH-2 serum resulted in a significant decrease in mortality and prolongation of survival time. This effect correlated with the neutralizing antibody titer of the serum against HVH-2 and was more pronounced when immune serum was administered 1 h after infection as compared with 24 h. These results suggest that administration of high-titer anti-HVH-2 immunoglobulins shortly after delivery could afford significant protection to the newborn of a mother with genital HVH-2 infection.

Entities:  

Mesh:

Year:  1975        PMID: 173653      PMCID: PMC415429          DOI: 10.1128/iai.12.6.1258-1261.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  PRIMARY DISSEMINATED HERPES SIMPLEX OF THE NEWBORN.

Authors:  C E WHEELER; W D HUFFINES
Journal:  JAMA       Date:  1965-02-08       Impact factor: 56.272

2.  Fulminating infection with herpes-simplex virus in premature and newborn infants.

Authors:  J G WHITE
Journal:  N Engl J Med       Date:  1963-08-29       Impact factor: 91.245

3.  Diagnosis of Herpesvirus hominis infections in a general hospital laboratory.

Authors:  L Hanna; H Keshishyan; E Jawetz; V R Coleman
Journal:  J Clin Microbiol       Date:  1975-03       Impact factor: 5.948

4.  Cell-mediated immunity to Herpes simplex in humans: lymphocyte cytotoxicity measured by 51-Cr release from infected cells.

Authors:  A S Russell; J S Percy; T Kovithavongs
Journal:  Infect Immun       Date:  1975-02       Impact factor: 3.441

5.  Evaluation of four antiviral agents in the treatment of herpes simplex encephalitis in a rat model.

Authors:  M I Marks
Journal:  J Infect Dis       Date:  1975-01       Impact factor: 5.226

6.  Herpes simplex virus as the cause of fulminating visceral disease and hepatitis in infancy; report of eight cases and isolation of the virus in one case.

Authors:  W W ZUELZER; C S STULBERG
Journal:  AMA Am J Dis Child       Date:  1952-04

Review 7.  Herpes simplex infections in hematologic malignancies.

Authors:  S A Muller; E C Herrmann; R K Winkelmann
Journal:  Am J Med       Date:  1972-01       Impact factor: 4.965

8.  Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus.

Authors:  S L Shore; A J Nahmias; S E Starr; P A Wood; D E McFarlin
Journal:  Nature       Date:  1974-09-27       Impact factor: 49.962

9.  Disseminated herpes simplex with encephalitis in a neonate. Treatment with idoxuridine.

Authors:  B Golden; W E Bell; A P McKee
Journal:  JAMA       Date:  1969-08-25       Impact factor: 56.272

10.  Resistance of female mice to vaginal infection induced by Herpesvirus hominis type 2: effects of immunization with Mycobacterium bovis, intravenous injection of specific Herpesvirus hominis type 2 antiserum, and a combination of these procedures.

Authors:  M B Baker; C L Larson; R N Ushijima; F D Anderson
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

View more
  16 in total

1.  Host defenses in herpes simplex infections of the nervous system: effect of antibody on disease and viral spread.

Authors:  R R McKendall; T Klassen; J R Baringer
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

2.  Protective effect of an oral infection with herpes simplex virus type 1 against subsequent genital infection with herpes simplex virus type 2.

Authors:  B Sturn; K E Schneweis
Journal:  Med Microbiol Immunol       Date:  1978-07-04       Impact factor: 3.402

3.  Recombinant interleukin-1 alpha, interleukin-2 and M-CSF-1 enhance the survival of newborn C57BL/6 mice inoculated intraperitoneally with a lethal dose of herpes simplex virus-1.

Authors:  C Berkowitz; Y Becker
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Pathogenesis of latent herpes simplex virus infection of the trigeminal ganglion in guinea pigs: effects of age, passive immunization, and hydrocortisone.

Authors:  R B Tenser; G D Hsiung
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

5.  Interleukin-12- and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus type 1.

Authors:  S Vollstedt; M Franchini; G Alber; M Ackermann; M Suter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Kinetics and genetics of herpes simplex virus-induced antibody formation in mice.

Authors:  A Knoblich; J Görtz; V Härle-Grupp; D Falke
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

7.  Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; S Bacchetti; W E Rawls
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

8.  Role of antibody in primary and recurrent herpes simplex virus infection.

Authors:  A Simmons; A A Nash
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

9.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

10.  Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.

Authors:  R D Dix; L Pereira; J R Baringer
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.